Panbela Therapeutics, Inc. (PBLA)
USD 0.26
(-3.7%)
USD 0.26
(-3.7%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -25.64 Million USD | 28.22% |
| 2022 | -35.73 Million USD | -256.95% |
| 2021 | -10.01 Million USD | -73.97% |
| 2020 | -5.75 Million USD | -33.13% |
| 2019 | -4.32 Million USD | -11.08% |
| 2018 | -3.89 Million USD | 35.32% |
| 2017 | -6.01 Million USD | -16.41% |
| 2016 | -5.16 Million USD | 5.07% |
| 2015 | -5.44 Million USD | -814.58% |
| 2014 | 761.84 Thousand USD | 83.42% |
| 2013 | 415.34 Thousand USD | -23.21% |
| 2012 | 540.9 Thousand USD | 262.5% |
| 2011 | 149.21 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -6.72 Million USD | 4.56% |
| 2024 Q2 | -8.1 Million USD | -20.47% |
| 2023 Q3 | -7.84 Million USD | -33.5% |
| 2023 FY | -25.64 Million USD | 28.22% |
| 2023 Q1 | -4.86 Million USD | -48.35% |
| 2023 Q2 | -5.87 Million USD | -20.93% |
| 2023 Q4 | -7.04 Million USD | 10.18% |
| 2022 Q2 | -22.99 Million USD | -474.33% |
| 2022 Q1 | -4 Million USD | -64.77% |
| 2022 FY | -35.73 Million USD | -256.95% |
| 2022 Q4 | -3.27 Million USD | 37.15% |
| 2022 Q3 | -5.21 Million USD | 77.34% |
| 2021 FY | -10.01 Million USD | -73.97% |
| 2021 Q2 | -2.22 Million USD | 0.98% |
| 2021 Q4 | -2.43 Million USD | -9.95% |
| 2021 Q3 | -2.21 Million USD | 0.72% |
| 2021 Q1 | -2.24 Million USD | -273.46% |
| 2020 Q2 | -1.1 Million USD | -3.56% |
| 2020 Q4 | 1.29 Million USD | 164.93% |
| 2020 Q3 | -1.99 Million USD | -80.8% |
| 2020 Q1 | -1.06 Million USD | 77.72% |
| 2020 FY | -5.75 Million USD | -33.13% |
| 2019 Q4 | -4.78 Million USD | -256.48% |
| 2019 Q3 | -1.34 Million USD | -23.35% |
| 2019 Q2 | -1.08 Million USD | -66.62% |
| 2019 Q1 | -653 Thousand USD | 88.24% |
| 2019 FY | -4.32 Million USD | -11.08% |
| 2018 Q1 | -1.23 Million USD | 86.66% |
| 2018 FY | -3.89 Million USD | 35.32% |
| 2018 Q4 | -5.55 Million USD | -505.45% |
| 2018 Q3 | -917 Thousand USD | 16.33% |
| 2018 Q2 | -1.09 Million USD | 11.47% |
| 2017 Q4 | -9.27 Million USD | -787.85% |
| 2017 Q1 | -1.99 Million USD | -154.34% |
| 2017 Q2 | -1.16 Million USD | 41.73% |
| 2017 Q3 | -1.04 Million USD | 10.07% |
| 2017 FY | -6.01 Million USD | -16.41% |
| 2016 Q4 | -784 Thousand USD | 30.93% |
| 2016 FY | -5.16 Million USD | 5.07% |
| 2016 Q2 | -949 Thousand USD | 2.67% |
| 2016 Q3 | -1.13 Million USD | -19.6% |
| 2016 Q1 | -975 Thousand USD | 52.46% |
| 2015 Q2 | 149.05 Thousand USD | 5.44% |
| 2015 FY | -5.44 Million USD | -814.58% |
| 2015 Q4 | -2.05 Million USD | -166.38% |
| 2015 Q3 | -770 Thousand USD | -616.58% |
| 2015 Q1 | 141.37 Thousand USD | -68.94% |
| 2014 Q3 | 149.87 Thousand USD | -3.49% |
| 2014 FY | 761.84 Thousand USD | 83.42% |
| 2014 Q2 | 155.28 Thousand USD | 10478.07% |
| 2014 Q1 | 1468.00 USD | -99.64% |
| 2014 Q4 | 455.21 Thousand USD | 203.74% |
| 2013 Q3 | 15.88 Thousand USD | 552.09% |
| 2013 Q2 | -3513.00 USD | -4647.3% |
| 2013 FY | 415.34 Thousand USD | -23.21% |
| 2013 Q4 | 403.05 Thousand USD | 2437.8% |
| 2013 Q1 | -74.00 USD | -100.04% |
| 2012 FY | 540.9 Thousand USD | 262.5% |
| 2012 Q3 | 146.47 Thousand USD | -12.72% |
| 2012 Q4 | 186.11 Thousand USD | 27.06% |
| 2012 Q1 | 40.48 Thousand USD | 0.0% |
| 2012 Q2 | 167.82 Thousand USD | 314.56% |
| 2011 FY | 149.21 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| America Great Health | 168.58 Thousand USD | 15312.827% |
| Ampio Pharmaceuticals, Inc. | -250 Thousand USD | -10158.8% |
| Aridis Pharmaceuticals, Inc. | - USD | Infinity% |
| Biora Therapeutics, Inc. | -551 Thousand USD | -4554.628% |
| Bio-Path Holdings, Inc. | -178 Thousand USD | -14308.427% |
| Better Therapeutics, Inc. | -2.72 Million USD | -839.795% |
| Calithera Biosciences, Inc. | -1.38 Million USD | -1751.769% |
| Comera Life Sciences Holdings, Inc. | 422.71 Thousand USD | 6167.251% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -22.91 Million USD | -11.903% |
| Eloxx Pharmaceuticals, Inc. | - USD | Infinity% |
| Evelo Biosciences, Inc. | - USD | Infinity% |
| Evolutionary Genomics, Inc. | -1.02 Million USD | -2410.737% |
| Finch Therapeutics Group, Inc. | -7.09 Million USD | -261.633% |
| Galera Therapeutics, Inc. | -259 Thousand USD | -9802.317% |
| Innovation1 Biotech Inc. | -52.69 Thousand USD | -48567.881% |
| Kiromic BioPharma, Inc. | -2.79 Million USD | -817.307% |
| Molecular Templates, Inc. | 50.39 Million USD | 150.892% |
| Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | -21398.805% |
| NexImmune, Inc. | -1.02 Million USD | -2402.215% |
| Orgenesis Inc. | -5.72 Million USD | -347.983% |
| Point of Care Nano-Technology, Inc. | -4601.00 USD | -557322.3% |
| PaxMedica, Inc. Common Stock | - USD | Infinity% |
| Scopus BioPharma Inc. | - USD | Infinity% |
| Sorrento Therapeutics, Inc. | 29.38 Million USD | 187.273% |
| Statera Biopharma, Inc. | -488.31 Thousand USD | -5152.153% |
| TRACON Pharmaceuticals, Inc. | -232 Thousand USD | -10954.741% |
| Trevena, Inc. | 1.45 Million USD | 1862.68% |
| Vaxxinity, Inc. | -2.23 Million USD | -1048.03% |
| Vaccinex, Inc. | -16 Million USD | -60.254% |
| Vicapsys Life Sciences, Inc. | - USD | Infinity% |
| Viracta Therapeutics, Inc. | -492 Thousand USD | -5112.805% |
| ZIVO Bioscience, Inc. | 11.61 Thousand USD | 221004.393% |